Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atrium Medical Corporation

http://www.atriummed.com/atrium.asp

Latest From Atrium Medical Corporation

Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Deal Watch Business Strategies

Ocuphire Chalks Up Another Phase III Success For Nyxol

The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.

Business Strategies Ophthalmic

Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation

Nyxol is almost set for an NDA filing for reversal of dilation during eye exams/surgery. The reformulation of phentolamine is also being studied in presbyopia, setting up possible competition with AbbVie’s Vuity.

Clinical Trials Business Strategies

Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?

Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.

Tech Transfer Round-Up Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register